Skip to content

Cardiovascular and Renal Outcomes of Integrated Management of Blood Pressure and Other Cardiometabolic Risks in Hypertensives

Cardiovascular and Renal Outcomes of Integrated Management of Blood Pressure and Other Cardiometabolic Risks in Hypertensives:a Multicenter Prospective Cohort Study (UPDATE-cohort)

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04531124
Enrollment
30000
Registered
2020-08-28
Start date
2020-09-01
Completion date
2026-02-28
Last updated
2020-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Risk Factor, Hypertension, Renal Disease

Brief summary

this clinical trial is designed to study the cardiovascular and renal outcomes of hypertensives after an integrated management of blood pressure and other cardiometabolic risks. it is a multicenter prospective cohort study.

Interventions

OTHERintegrated management

establish an integrated management on cardio-metabolic risk factors including hypertension by updating and upgrading the daily practice of practitioners and screening patients

Sponsors

Huashan Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Outpatients from departments of Cardiology, Endocrinology, Nephrology, Neurology, Geriatrics or General Internal Medicine. 2. Diagnosed as hypertension. Diagnostic criteria: 1)The office BP measured at the day of visit and at least one time before that day were above the cut-off values ( ≥140 mmHg SBP and/or ≥90 mmHg DBP); 2)for patients with normal BP at the day of visit, they should have already been given pre-treatment with antihypertensive drugs ≥ 2 weeks. 3. Voluntary participation.

Exclusion criteria

1. Patients aged\< 18 years old. 2. Patients without a definite diagnosis of hypertension(for instance, if the patient has been taking antihypertensive drugs irregularly, it is difficult to confirm the diagnosis of hypertension). 3. Patients with a definite diagnosis of secondary hypertension. 4. Patients are diagnosed dyslipidemia with clear cause, such as nephrotic syndrome, severe hypothyroidism, terminal stage of malignancy, etc. 5. Patients are diagnosed end-stage renal disease, hemodialysis, and peritoneal dialysis patients. 6. Patients diagnosed with mental abnormalities who are unable to complete the questionnaire. 7. Patients have once participated in this research during this study cycle(to avoid repeated participation).

Design outcomes

Primary

MeasureTime frameDescription
complex outcomefollow-up 1 yearnumber of participants with 3P-MACE events(cardiovascular deaths, non-fatal myocardial infarction, non-fatal stroke)
coronary angioplastyfollow-up 1 yearnumber of participants with coronary angioplasty
acute renal failurefollow-up 1 yearnumber of participants with acute renal failure(eGFR decreases by 50% or \<15ml/min/1.73m2, dialysis or renal death)
acute heart failurefollow-up 1 yearnumber of participants with acute heart failure(non-scheduled hospitalizations due to heart failure or required intravenous medication)

Countries

China

Contacts

Primary Contactyong li, professor
liyong606@126.com+86 13801753494
Backup Contactxiufang gao, associate professor
sophiakao@126.com+86 13788908071

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026